Relmada Therapeutics To Present At LD MICRO Conference
Information contained on this page is provided by an independent third party content provider. WorldNow and this Station make no warranties or representations in connection therewith.NEW YORK, Nov. 24, 2014 /PRNewswire/ Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical stage company developing novel therapies for the treatment of chronic pain, announced today that Sergio Traversa, chief executive officer, is scheduled to present at the LD "Anadrol 50" MICRO "MAIN Event" Micro Cap Growth Conference on Wednesday, December 3, 2014. The conference will be held at Testosterone Enanthate Cycle Length the Luxe Sunset Bel Air Hotel, which is located at 11461 Sunset Boulevard in Los Angeles, California. EST and will be available as a live and archived webcast. The replay will be available for 90 days following the live broadcast.Mr. Traversa and other members of the management team will be available for one on one meetings at the conference.LD MICRO is an investment newsletter firm that focuses on finding undervalued companies in the micro cap space. Since 2002, the firm has published reports on select companies throughout the year. The firm hosts the LD MICRO "Main Event" Micro Cap Growth Conference for investors in December of each year. This year conference will feature presentations by over 240 publicly traded companies and is expected to attract more than 1,000 attendees.About Relmada Therapeutics, Inc.Relmada Therapeutics is a "Achat Anabolisant Belgique" clinical stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at various stages of "Anaboliset Aineet" development including LevoCap ER, its "Anaboliset Aineet" abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; d methadone, its N methyl D aspartate (NMDA) receptor antagonist for neuropathic pain; BuTab ER, its oral dosage form of the opioid analgesic buprenorphine; and MepiGel, its orphan drug designated topical formulation of the local anesthetic mepivacaine. The Company product development efforts are guided by the internationally recognized Sustanon 250 Kaina scientific expertise of its research team. The Company approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.This news release contains "forward looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward looking statements may include statements regarding product development, product potential, or financial performance. No forward looking statement can Winstrol W Tabletkach Cykl be guaranteed and actual results may differ materially from those projected. (Photo: Columbia Pictures / MGN)Don't Forget The Whipped "buy cheap jintropin online" Cream! Last Minute Shoppers Pack Grocery StoresDon't Forget The Whipped Cream! Last Minute Shoppers Pack Grocery StoresShoppers pack grocery storesManagers say don't fret if you're running behind and need something. And then you can come in and work in the details."And Ginger Powell added, "We're done. This is the details. And then you can come in and work in the details."And Ginger Powell added, "We're done. This is the details.